Frank Torti

Revolution Health is a leading consumer-centric health company founded to transform how people approach their overall health and wellness. By putting individuals at the center of their own healthcare, Revolution Health allows them to make informed choices and offers more convenience and control over their individual healthcare decisions.

Tufts Associated Health Plans, Inc. provides healthcare plans. It offers health care coverage options to individuals and employer groups. The firm also offers choice tiered network option plan and Steward Community Choice, a community-based plan, developed in conjunction with Steward Health Care System. The company was founded by Morton A. Madoff in 1979 and is headquartered in Watertown, MA.

Tarveda Therapeutics, Inc. discovers and develops cancer therapeutics and drugs. Its proprietary technology, assets and expertise are built around an integrative research and development process that brings together new-molecule drug discovery engine and patented nanoparticle engineering platform. The company was founded by Omid C. Farokhzad, Stephen J. Lippard and Robert S. Langer Jr., in 2011 and is headquartered in Watertown, MA.

Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY.

OrphoMed, Inc. develops and manufactures pharmaceutical products. The company was founded Pankaj Jay Pasricha and Frank Steinberg and is headquartered in Mill Valley, CA.

Part of Sio Gene Therapies, Inc., Axovant Sciences, Inc. is a private company that manufactures and distributes pharmaceutical products. The company is based in New York, NY.

Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY.

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Part of Novast Holdings Ltd., Novast Pharmaceuticals Ltd. develops and distributes pharmaceutical drugs. The private company is based in Nantong, China.

Part of Roivant Sciences Ltd., Dermavant Sciences, Inc. develops biological products. The private company is based in Raleigh, NC. Todd Zavodnick has been the CEO of the company since 2018.

Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY.

Xoc Pharmaceuticals, Inc. operates as Biopharmaceutical Company. It focuses on the development of innovative therapeutics. The company was founded by Scott W. Borland, Miguel Guzman and Lisa Borland and is headquartered in Los Gatos, CA.

Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries.

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom.

Part of Roivant Sciences Ltd., Genevant Sciences Corp. operates as a Canadian biopharmaceutical company. The private company is based in Burnaby, Canada. The CEO of the company is Bo Rode Hansen.

New Enterprise Associates LLC is an alternative investment manager. The private company is based in Timonium, MD. The company was founded in 1978 by Chuck Newhall, C. Richard Kramlich.

Altavant Sciences, Inc. is a clinical stage biopharmaceutical company, which provides therapies that treat respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH). The company is headquartered in Cary, NC.

Part of Roivant Sciences Ltd., Respivant Sciences, Inc. is a clinical-stage biopharmaceutical company that develops therapies for patients with respiratory diseases. The private company is based in San Diego, CA.

Dermavant Sciences Ltd. is a clinical-stage biopharmaceutical company which focuses on developing and commercializing therapeutics in medical dermatology. The company is developing a pipeline of therapies in medical dermatology and is currently advancing development programs for five product candidates which targets specific unmet needs in two of the immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis and acne. The company was founded on September 28, 2015 and is headquartered in London, the United Kingdom.

Immunovant, Inc. is a biopharmaceutical company, which engages in the development of therapies for autoimmune diseases. It focuses on its product pipeline, IMVT-1401, which is a human recombinant anti-neonatal Fc receptor monoclonal antibody for the treatment of IgG mediated diseases. The company is headquartered in New York, NY.

Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY.

Part of Roivant Sciences Ltd., Immunovant Sciences Ltd. develops restorative therapies for autoimmune diseases. The private company is based in Hamilton, Bermuda. Immunovant Sciences was acquired by Health Sciences Acquisitions Corp. from Roivant Sciences Ltd. on December 19, 2019 for $863.06 million.